MX2020009441A - Metodos para tratar las enfermedades asociadas al vph. - Google Patents

Metodos para tratar las enfermedades asociadas al vph.

Info

Publication number
MX2020009441A
MX2020009441A MX2020009441A MX2020009441A MX2020009441A MX 2020009441 A MX2020009441 A MX 2020009441A MX 2020009441 A MX2020009441 A MX 2020009441A MX 2020009441 A MX2020009441 A MX 2020009441A MX 2020009441 A MX2020009441 A MX 2020009441A
Authority
MX
Mexico
Prior art keywords
hpv
methods
associated disease
immune cells
associated diseases
Prior art date
Application number
MX2020009441A
Other languages
English (en)
Inventor
Armon R Sharei
Scott Loughhead
Alfonso Vicente-Suarez
Matt Booty
Howard Bernstein
Katarina Blagovic
Kelan Hlavaty
Leeann Talarico
Melissa Myint
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Publication of MX2020009441A publication Critical patent/MX2020009441A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by a specific adjuvant, e.g. cytokines or CpG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

. La presente solicitud proporciona células inmunes que comprenden un antígeno del VPH y un adyuvante, métodos para fabricar dichas células inmunes modificadas y métodos para usar dichas células inmunes modificadas para tratar una enfermedad asociada al VPH, prevenir una enfermedad asociada al VPH y/o para modular una respuesta inmune en un individuo con una enfermedad asociada al VPH.
MX2020009441A 2018-03-12 2019-03-11 Metodos para tratar las enfermedades asociadas al vph. MX2020009441A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862641988P 2018-03-12 2018-03-12
US201962794517P 2019-01-18 2019-01-18
US201962812225P 2019-02-28 2019-02-28
PCT/US2019/021703 WO2019178005A2 (en) 2018-03-12 2019-03-11 Methods for treating hpv-associated diseases

Publications (1)

Publication Number Publication Date
MX2020009441A true MX2020009441A (es) 2021-01-08

Family

ID=65904594

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009441A MX2020009441A (es) 2018-03-12 2019-03-11 Metodos para tratar las enfermedades asociadas al vph.

Country Status (18)

Country Link
US (1) US20210038709A1 (es)
EP (1) EP3765073A2 (es)
JP (1) JP2021517895A (es)
KR (1) KR20200130371A (es)
CN (1) CN112105383A (es)
AU (1) AU2019234549A1 (es)
BR (1) BR112020018609A2 (es)
CA (1) CA3093826A1 (es)
CO (1) CO2020012583A2 (es)
CR (1) CR20200461A (es)
IL (1) IL277190A (es)
MA (1) MA52003A (es)
MX (1) MX2020009441A (es)
PE (1) PE20201201A1 (es)
PH (1) PH12020551437A1 (es)
SG (1) SG11202008863XA (es)
TW (1) TW202003025A (es)
WO (1) WO2019178005A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
PE20220379A1 (es) * 2019-02-28 2022-03-18 Sqz Biotechnologies Co Suministro de biomoleculas a pbmc para modificar una respuesta inmune
US11679388B2 (en) 2019-04-08 2023-06-20 Sqz Biotechnologies Company Cartridge for use in a system for delivery of a payload into a cell
MX2021013974A (es) 2019-05-14 2022-02-10 Prometheus Biosciences Inc Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
CN112007149A (zh) * 2019-05-29 2020-12-01 思格(苏州)生物科技有限公司 一种新型复合免疫佐剂及其应用
CN110846318A (zh) * 2019-11-29 2020-02-28 华中科技大学同济医学院附属同济医院 治疗hpv感染的纳米粒制剂中新的靶向序列以及新pbae的制备方法
US20230181712A1 (en) 2020-05-11 2023-06-15 Hoffmann-La Roche Inc. Combination therapy with modified pbmcs and an immunoconjugate
EP4206215A1 (en) * 2020-07-24 2023-07-05 West China Hospital of Sichuan University Ebv-targeted allogeneic b cell vaccine and preparation method therefor
JP2023535982A (ja) 2020-07-29 2023-08-22 スクイーズ バイオテクノロジーズ カンパニー 無核細胞を使用して変異型Ｒａｓに対する免疫応答を刺激する方法
KR20230058389A (ko) 2020-07-29 2023-05-03 에스큐지 바이오테크놀로지스 컴퍼니 유핵 세포를 사용해 돌연변이체 ras에 대한 면역 반응을 자극하는 방법
CN116406283A (zh) * 2020-09-02 2023-07-07 Sqz生物技术公司 用于使用有核细胞刺激对蛋白质的hla未知免疫应答的方法
EP4271407A1 (en) 2020-12-29 2023-11-08 SQZ Biotechnologies Company Formulations of activating antigen carriers
US20220241392A1 (en) * 2020-12-29 2022-08-04 Sqz Biotechnologies Company Formulations of pbmcs
WO2022147443A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Methods for treating cancers with activating antigen carriers
TW202241466A (zh) * 2020-12-29 2022-11-01 美商Ｓｑｚ生物科技公司 以經修飾ｐｂｍｃ治療癌症之方法
WO2023010090A1 (en) 2021-07-29 2023-02-02 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2023087009A1 (en) 2021-11-11 2023-05-19 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
WO2024026491A2 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Enhanced antigen presenting cell formulations
WO2024026492A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Methods for treating cancer with enhanced antigen presenting cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046251A1 (fr) * 2006-10-19 2008-04-24 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées
US9562075B2 (en) * 2007-05-31 2017-02-07 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
WO2010132867A1 (en) * 2009-05-15 2010-11-18 Irx Therapeutics, Inc. Vaccine immunotherapy
HUE047507T2 (hu) 2011-10-17 2020-04-28 Massachusetts Inst Technology Intracelluláris célbajuttatás
ES2745472T3 (es) * 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
CA2964392A1 (en) * 2014-10-31 2016-05-06 Massachussetts Institute Of Technology Delivery of biomolecules to immune cells
SG11201702997YA (en) * 2014-11-04 2017-05-30 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
CN108138118B (zh) * 2015-09-04 2023-01-06 Sqz生物技术公司 由具孔表面介导的生物分子的细胞内递送
JP7033535B2 (ja) * 2016-01-12 2022-03-10 スクイーズ バイオテクノロジーズ カンパニー 複合体の細胞内送達
CN112574317B (zh) * 2017-01-24 2023-12-05 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用

Also Published As

Publication number Publication date
PE20201201A1 (es) 2020-11-11
PH12020551437A1 (en) 2021-09-06
CN112105383A (zh) 2020-12-18
CR20200461A (es) 2021-03-11
SG11202008863XA (en) 2020-10-29
EP3765073A2 (en) 2021-01-20
WO2019178005A2 (en) 2019-09-19
MA52003A (fr) 2021-01-20
US20210038709A1 (en) 2021-02-11
RU2020132524A (ru) 2022-04-13
IL277190A (en) 2020-10-29
CO2020012583A2 (es) 2020-10-30
JP2021517895A (ja) 2021-07-29
WO2019178005A3 (en) 2019-10-17
CA3093826A1 (en) 2019-09-19
BR112020018609A2 (pt) 2020-12-29
TW202003025A (zh) 2020-01-16
KR20200130371A (ko) 2020-11-18
AU2019234549A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
MX2020009441A (es) Metodos para tratar las enfermedades asociadas al vph.
PH12020551436A1 (en) Intracellular delivery of biomolecules to modify immune response
MX2021002415A (es) Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2021010320A (es) Administracion de biomoleculas a celulas mononucleares de sangre periferica (pbmc) para modificar una respuesta inmunitaria.
WO2017160717A9 (en) Method of treating diseases using kinase modulators
WO2017172771A3 (en) Treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
WO2018151811A3 (en) Use of tgf alpha for the treatment of diseases and disorders
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
ZA202205927B (en) Anti-yellow fever virus antibodies, and methods of their generation and use
WO2020099352A3 (en) Immunogenic peptides with new oxidoreductase motifs
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
CO2021017317A2 (es) Células seguras e invisibles para el sistema inmunitario
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
WO2020092743A3 (en) Methods of treating diseases using kinase modulators
WO2019213606A3 (en) Solid forms of cerdulatinib
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2020008801A (es) Células presentadoras de antígeno universal y usos de las mismas.
WO2019099578A8 (en) Use of imidazopyrimidine for modulating human immune response